A study of the expression of Cyclin e and its isoforms in tumor and adjacent mucosa, correlated to patient outcome in early colon cancer

Acta Oncologica

Volumn 49, Issue 1, 2010, Pages 63-69

  Corin, Irina ^a   Larsson, Lisa ^a   Bergström, Jörgen ^b   Gustavsson, Bengt ^a   Derwinger, Kristoffer ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; ISOPROTEIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; CORRELATION ANALYSIS; EARLY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; COLONIC NEOPLASMS; CYCLIN E; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

EID: 76649106760     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903268049     Document Type: Article

References (22)

1. Crawford NP, Colliver DW, Galandiuk S. Tumor markers and colorectal cancer: Utility in management. J Surg Oncol 2003; 84:239-48.
2. Keyomarsi K, Tucker SL, Buchholz T A, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566-75.
3. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004; 64:3198-208.
4. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994; 14:1669-79.
5. Cassia R, Moreno-Bueno G, Rodriguez-Perales S, Hardisson D, Cigudosa JC, Palacios J. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol 2003; 201:589-95.
6. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13:41-7.
7. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413 (6853) : 316-22.
8. Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004; 428 (6978) : 77-81.
9. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001; 21:6254-69.
10. Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle 2003; 2:461-6.
11. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 2004; 23:2648-57.
12. Milne AN, Carvalho R, Jansen M, Kranenbarg EK, van de Velde CJ, Morsink FM, et al. Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival. J Clin Pathol 2008; 61:311-6.
13. Corin I, Di Giacomo MC, Lastella P, Bagnulo R, Guanti G, Simone C. Tumor-specific hyperactive low-molecular-weight cyclin E isoforms detection and characterization in non-metastatic colorectal tumors. Cancer Biol Ther 2006; 5:198-203.
14. Hur K, Kim JR, Yoon BI, Lee JK, Choi JH, Oh GT et al. Overexpression of cyclin D1 and cyclin E in 1,2-dimethyl-hydrazine dihydrochloride-induced rat colon carci nogenesis. J Vet Sci 2000; 1:121-6.
15. Yasui W, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin E in colorectal adenomas and adenocarcinomas: Correlation with expression of Ki-67 antigen and p53 protein. Virchows Arch 1996; 429:13-9.
16. Sutter T, Doi S, Carnevale KA, Arber N, Weinstein IB. Expression of cyclins D1 and E in human colon adenocarcinomas. J Med 1997; 28:285-309.
17. Feng M, Pei F, Yang G, Mao Z, Wang S. Expression of p53 and p21 protein in transitional mucosa adjacent to rectal carcinoma and its clinical implication. J Tongji Med Univ 2000; 20:220-1.
18. Chen LC, Hao CY, Chiu YS, Wong P, Melnick JS, Brotman M, et al. Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res 2004; 64:3694-700.
19. Libertini SJ, Robinson BS, Dhillon NK, Glick D, George M, Dandekar S, et al. Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. Cancer Res 2005; 65:10700-8.
20. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, et al. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 2005; 65:692-7.
21. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, et al. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 2007; 67:7212-22.
22. Lim YJ, Kim YH, Ahn GH, Chun HK, Jang WY, Lee JH, et al. Cyclin E, p27 and mutant p53 do not predict the prognosis in AJCC stage II colorectal carcinomas. Korean J Gastroenterol 2004; 44:314-20.